GLP1R and obesity disorder: A change in the microbiome of mice with diet-induced obesity treated with GLP-1 RA liraglutide (0.2 mg/kg, BID) and dual GLP-1/GLP-2 receptor agonist (GUB09–145, 0.04 mg/kg, BID) was observed, with potential to influence SCFAs production [101].